Article citationsMore>>
Rini, B.I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T.E., Michaelson, M.D., Gorbunova, V.A., Gore, M.E., Rusakov, I.G., Negrier, S., Ou, Y.-C., Castellano, D., Lim, H.Y., Uemura, H., Tarazi, J., Cella, D., Chen, C., Rosbrook, B., Kim, S. and Motzer, R.J. (2011) Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial. The Lancet, 37, 1931-1939.
http://dx.doi.org/10.1016/S0140-6736(11)61613-9
has been cited by the following article:
-
TITLE:
Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma
AUTHORS:
Takeshi Namekawa, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Takayuki Ohzeki, Yosuke Sato, Junryo Rii, Hirotsugu Uemura, Tomohiko Ichikawa, Takeshi Ueda
KEYWORDS:
Axitinib, Renal Cell Carcinoma, First Line
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.8,
July
28,
2015
ABSTRACT: Previous study
reported that patients treated with axitinib as second-line therapy had longer
median progression-free survival than those treated with sorafenib for
metastatic renal cell carcinoma (mRCC). In this study, we reviewed our
experience of axitinib as a first-line therapy for mRCC in Japanese patients,
focusing on its efficacy and safety. We retrospectively assessed 26 patients
treated with axitinib as a first-line therapy for mRCC from July 2010 to July
2014 at Chiba Cancer Center and Kinki University Hospital. Observation period
was 24.6 ± 18.3 months. The objective response rate was 50.0%, and the median
progression-free survival was 27.5 months. Overall survival was not estimable.
Common grade 3 adverse events were hypertension in 19 patients and proteinuria
in 5 patients. Axitinib demonstrated significant efficacy as a first-line therapy
in Japanese patients with mRCC. Careful monitoring and management of the
adverse effects may help to control its toxicities.
Related Articles:
-
Mamert Fulgence Yao Bathaix, Dramane Soro, Aboubacar Demba Bangoura, Adjéka Stanislas Doffou, Siaka Koné, Ya Henriette Kissy, Dimitri Hartrydt Kouamé, Aoudi Ousmane Dé, Mahassadi Kouamé Alassane, Attia Koffi Alain, Aya Thérèse N’dri Yoman
-
Constant Assi, Amadou Ouattara, Siaka Kone, Dramane Soro, Emile Allah-Kouadio, Claude Ghislain Kouakou, Nigué Luc, Benoît-Mathieu Camara, Marie-Jeanne Lohoues-Kouacou
-
Kouadio Vincent Asse, Kossonou Roland Yeboua, Richard Azagoh-Kouadio, Kouassi Christian Yao, Koko Aude Aka-Tanoh, Christelle Avi, Mocket Adolphe Ehouman, Kouie Jeannot Plo
-
Mireille Aye-Yayo, Vincent Yapo, Boidy Kouakou, Missa Louis Adjé, Adia Eusèbe Adjambri, Ebah Hermance Kassi, Taïratou Kamagate, Duni Sawadogo
-
Koffi Sébastien Ouffoué, Moreto Salla, Denis Yapo Kicho, Dodiomon Soro, Kouhété Philippe Da, Zanahi Félix Tonzibo